Japanese clinical practice guidelines for the management of kidney disease in cancer survivors" have been published. This guideline recommended several managements for nephrotoxicity of other agents than platinum such as the urinary alkylation during methotrexate administration, suspending of anti-angiogenetic agent for the grade 2 or more proteinuria, dose modification of bisphosphonate based on the renal function. Understanding the background of these recommendations will contribute for safe cancer chemotherapy.
|ジャーナル||Japanese Journal of Cancer and Chemotherapy|
|出版物ステータス||Published - 2017 3 1|
ASJC Scopus subject areas
- Cancer Research